#interferon

Rick Nash’s journey, born with Hep C, six treatments for Hepatitis C (HCV,) one transplant, and lots of friends and family.

Direct-acting antivirals lower the risk of cardiovascular disease to a greater extent than interferon-based regimens.

Nearly all those treated in a recent trial were cured.

Direct-acting antivirals lower this risk to a greater extent than interferon-based regimens.

Whether such recurrence is less likely after interferon treatment remains the source of some controversy in the hep C research community.

Hepatitis C knocked pro wrestler Devon “Hannibal” Nicholson out of the ring, but a cure landed him back in the fight.

A photographer helps his mom get cured of hep C after reading Hep magazine.

Connie Dewbre’s son convinced her to get cured of HCV again after visiting our Hep magazine website.

The link between the older interferon treatment and these cancers may be related to the drug’s low hep C cure rate.

A European liver transplant registry saw a decline in hep C as a cause of needing a transplant.

In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.

However, in a small subset of those with advanced fibrosis or cirrhosis, liver damage remains the same or worsens post-cure.

Fighting Hep C, using the fury to stoke the fire within.

Any previous apparent link between direct-acting antivirals, compared with interferon, and liver cancer was likely driven by other factors.

The FDA has expanded approval of the direct-acting antiviral treatments Sovaldi and Harvoni for adolescents ages 12 and older.

The antiviral drug, which for some people can be a beneficial adjunct to the new crop of hep C medications, has gotten a bad rap.